Objectives: The ongoing ASCEND trial of natalizumab utilizes a novel composite endpoint, comprised of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW) and 9-Hole Peg Test (9HPT) to assess disability progression in patients with secondary-progressive multiple sclerosis (SPMS), due to the limited ability of EDSS alone to assess disability progression in this patient population. Given that the ASCEND data are not available, data from the IMPACT study was used to assess the cost-effectiveness of SPMS treatments in an economic model capturing the interrelated changes of these measures for individual patients. This study presents the model concept and assesses its external predictability. MethOds: A discrete event simulation was developed to predict times to disability progressions on EDSS, T25FW, and 9HPTand the occurrence of relapses over time, using four parametric (Weibull) functions, each adjusted by a Cox model to ensure that each event time was estimated based on patients' baseline and time-varying factors. Each disability scale's value is updated as events occur. Data from the IMPACT study (n= 436, followed for 2 years) was extrapolated for longer term. Published data on EDSS from the University of British Columbia (UBC) MS database were used for long-term external validations. Results: The model closely replicated all four endpoints as observed in the IMPACT study at two years. The predicted times for 25% of patients to reach EDSS 8 were consistent with those from the UBC data, with 13.4 (model) vs. 14.8 (UBC) years from EDSS 3.5-4.5, and 8.7 vs. 8.6 years from EDSS 6.0. The distributions of T25FW and 9HPT by EDSS level predicted at 10 years were consistent with those observed from the IMPACT study. cOnclusiOns: This SPMS model reliably predicts short-and long-term disability levels, and can serve as the basis for economic evaluations of treatments for SPMS.
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IMPleMentatIon of PoPulatIon DynaMIcs In MoDellIng HealtH anD BuDget IMPact of an InteRventIon foR a cHRonIc DIsease WItH MultIPle DIsease suBtyPes
Tran-Duy A 1 , Boonen A 1 , Caro JJ 2 , Severens JL 3 1 Maastricht University Medical Center+, Maastricht, The Netherlands, 2 Evidera, Lexington, MA,
USA, 3 Erasmus University Rotterdam, Rotterdam, The Netherlands
Objectives: In a budget impact analysis (BIA), the population is supposed to include all patients eligible for the new intervention during the time span of decision: new incident cases and patients leaving due to death, cure, migration or other reasons, must be captured. Additionally, temporal changes in the actual number of individuals receiving the intervention must be quantified. While most of the guidelines for BIA emphasize this population dynamics aspect, recommendations on how to technically implement it are lacking. We introduce a method for implementing population dynamics in a chronic disease with multiple disease subtypes using object-oriented programming (OOP), and demonstrate its application in modelling health and budget impact of a treatment strategy for ankylosing spondylitis (AS). MethOds: A generic hierarchical patient class structure was developed to systematically organize the prevalent population and incident cohorts of patients with different disease subtypes. Using the concepts of inheritance and polymorphism in OOP, we formulated algorithms to efficiently compute health measures and resource utilization of individual patients in different classes, and to perform probabilistic sensitivity analysis. In the case study, a dynamic population model was developed to predict the burden of AS in the Dutch society over a 20-year period from January 1, 2015 onwards when a sequential treatment strategy including tumour necrosis factor antagonists was applied. Data for model parameterization were obtained from the Outcomes Assessment of AS International Study (OASIS) and literature. Results: The case study demonstrated that our dynamic population modelling method offers an efficient approach to quantify annual as well as total health and costs for different decision time spans. Annual direct costs incurred by the AS patients in the Dutch Society would range from 471 to 496 million Euros between 2015-2035. cOnclusiOns: Our method for implementation of population dynamics is efficient and generic, so it can be applied to other chronic diseases.
PRM102 BuDget IMPact analysIs of DelayeD-Release DIMetHylfuMaRate In tHe tReatMent of RelaPsIng-ReMIttIng MultIPle scleRosIs In Italy
Furneri G 1 , Marchesi C 2 , Santoni L 3 1 EBMA Consulting, Melegnano, Italy, 2 Biogen Spa, Milan, Italy, 3 Biogen, Milan, Italy Objectives: To evaluate the economic impact of a recently approved therapy, delayed-release dimethylfumarate (DMF; also known as gastro-resistant DMF), on the overall management costs of relapsing-remitting multiple sclerosis (RRMS) in Italy. MethOds: A budget impact model, adopting the perspective of the Italian National Healthcare Service (NHS), was used to compare healthcare costs of two different treatment scenarios: a) base-case, in which DMF is not reimbursed/funded by the NHS, vs. b) reimbursement-case, in which DMF is reimbursed and funded by the NHS. Healthcare costs sustained by the Italian NHS to manage the RRMS population (drug treatment, administration, therapy and disease monitoring, relapse management, treatment-related adverse events) have been calculated over 3 years and compared for the two scenarios. Impact of relapses for the disease modifying therapies (DMTs) included in the analysis was estimated using results from published literature. RRMS population treated with DMTs was estimated using Italian prevalence and incidence data. According to these estimates, the number of treated patients amounted to 35,100 at Year 1, 36,800 at Year 2, and 38,700 at Year 3. Results: According to current price and reimbursement conditions established by the Italian NHS, it was estimated that the introduction of DMF (reimbursementcase) would determine a decrease of the budget impact, if compared with the base-case (non-reimbursement case). Over three years, the budget impact would be € 1,388,640,000 in the base-case and € 1,359,800,000 in the reimbursement-case (-€ 28,840,000; -2.1% relative budget variation). The main drivers for cost-saving were pharmacological treatment costs and reduced burden of relapses (corresponding to about 1,500 avoided relapses). cOnclusiOns: At the current reimbursement increased risk of secondhand smoking on morbidity and mortality. The impact of secondhand smoking was included in a previously published Markov model called the BENESCO model to estimate the economic burden in Korea. Transition probabilities and costs were acquired from Korean public data. The time horizon was lifetime and assumed 5% discount rate for costs. The estimated cost was compared with published estimates to establish external validity of the model. Results: 13.7% of women (≥ 19 years old) and 30.7% of children (13-18 years old) from general population were exposed to secondhand smoke in household. Relative risks of secondhand smoking related diseases were lung cancer 1.9(95% CI 1.0-3.5), coronary heart disease 1.27(95% CI: 1.19-1.36), stroke 1.25(95% CI: 1.12-1.38) in women married for smoking husbands. The odd of Asthma onset was 1.32 times higher in children whose father smokes. The estimated costs were increased by 10 to 50%, compared with the model without the impact of secondhand smoking. cOnclusiOns: Cigarette smoking and exposure to secondhand smoke is associated with significant economic burden. Policymakers should be advised that tobacco control should be aimed not just smokers, but those who are vulnerable to secondhand smoking, especially women and children lived with smokers.
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InvestIgatIng tHe IMPact of conteMPoRaRy RIsk factoRs foR DIaBetes coMPlIcatIons anD tHeIR evolutIon on RIsk PReDIctIon usIng tHe ukPDs 82 equatIons
McEwan P 1 , Foos V 2 , Lamotte M 3 1 Health Economics and Outcomes Research Ltd, Monmouth, UK, 2 IMS Health, Basel, Switzerland, 3 IMS Health, Vilvoorde, Belgium Objectives: UKPDS 82 provided updated and new event equations for use in type 2 diabetes mellitus (T2DM) that include new risk factor (RF) predictors. These new RFs do not routinely get reported in clinical studies; consequently, the objective of this study research was to report plausible baseline RF values and their timedependent trajectories and quantify their impact upon predicted complication rates. MethOds: Availability of baseline and time-dependent RF data was assessed using a pragmatic literature review. Univariate sensitivity analysis of the UKPDS 82 equations (over a 40-year horizon ) was undertaken to assess the impact of lowdensity lipoprotein [LDL]; microalbuminuria (MA); heart rate (HR); white blood cell count (WBC): haemoglobin (Hb) and estimated glomerular filtration rate (eGFR) on predicted diabetes complications per 1,000 patients, using UKPDS baseline values (varied within the 95% central range). Results: The review identified 32 studies reporting baseline RF values typically consistent with UKPDS (review versus UKPDS): LDL (2.6-3.8 versus 3.49mmol/l); MA (11-45% versus 6.5%); HR (67-72 versus 72bpm); WBC (5.7-7.9 versus 6.6x106/ml); Hb (12.4-14 versus 14.5g/dl); the exception was eGFR where baseline values (33-101 versus 77.5ml/min/1.73m2) and decline (0.3-5.2ml/min/1.73m2/year) varied widely. Utilising UKPDS 82 baseline values resulted in 877 macrovascular and 133 microvascular events predicted with 691 to 1,181 and 116 to 182, respectively, predicted in sensitivity analyses; drivers of risk were LDL and eGFR. Varying eGFR decline between 0.3 to 5.2ml/min/1.73m2/year resulted in annual event rates for end stage renal disease (ESRD) between 0.021 to 1.251%; holding eGFR constant over time resulted in ESRD annual event rate of 0.020%, significantly lower than observed in UKPDS (0.13%). cOnclusiOns: Appropriate specification of RF is important in diabetes modelling. This study suggests that the UKPDS profile is generally consistent with other identified T2DM populations. Modelling a decline in eGFR improved the predictive accuracy of ESRD incidence.
PRM99 BetteR ReIMBuRseMent DecIsIon-MakIng BaseD on exPecteD cost-effectIveness: usIng value of InfoRMatIon DecIsIon analysIs to IMPRove tHe DesIgn anD effIcacy of a PHase III PRogRaM foR eRlotInIB
Mukherjee SC 1 , Latimer N 2 , Richards P 2 , Nixon RM 3 , Hall PS 4 1 Pharmerit International, York, UK, 2 University of Sheffield, Sheffield, UK, 3 Novartis Pharma AG, Basel, Switzerland, 4 University of Edinburgh, Edinburgh, UK Objectives: Erlotinib, a tyrosine-kinase inhibitor, has been recommended for use in non-small cell lung cancer patients harbouring an EGFR mutation. The present study is retrospective in nature; using published clinical trial data for erlotinib, it demonstrates how an analysis of Phase II data could be used to identify what data Phase III studies should focus on collecting. MethOds: Phase II data were identified through a targeted literature search and used to determine the cost-effectiveness of erlotinib, utilising a simple Markov model framework. Data from the literature were mapped to model inputs using statistical data analysis methods. Value of Information (VOI) analysis tools, such as Expected Value of Perfect Information (EVPI) and Expected Value of Partial Perfect Information (EVPPI) were used to identify those uncertain parameters having research value in a prospective Phase III program. These findings helped to optimise the design of a hypothetical Phase III trial for erlotinib that could collect data that is most relevant for reimbursement decision-making. Results: At a cost-effectiveness threshold of £30,000 per quality-adjusted life year (QALY) gained, the population EVPI was £3,269,358, indicating that further research is valuable. The EVPPI identified the log hazards of erlotinib (intervention) and gefitinib (comparator) for progression-free survival and overall survival as the parameters for which uncertainty was the most valuable. The value of the uncertainty associated with other parameters, such as utilities and costs, was much lower. Hence, subsequent studies should focus on providing further information on efficacy parameters rather than on utilities and costs. cOnclusiOns: Undertaking VOI analysis on data collected at Phase II can help ensure that Phase III trials are designed efficiently, in turn ensuring that uncertainty in future decision-making is minimised. This model demonstrated the VOI from a public policy perspective. This could be extended to other perspectives to ensure greater relevance in different settings.
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MoDelIng tHe natuRal HIstoRy of seconDaRy-PRogRessIve MultIPle scleRosIs: a neW MoDelIng aPPRoacH usIng DIscRete event sIMulatIon
